Treating soft tissue sarcomas with adjuvant chemotherapy

Current Treatment Options in Oncology

Volumn 12, Issue 1, 2011, Pages 21-31

  Patrikidou, Anna ^a   Domont, Julien ^a   Cioffi, Angela ^a   Le Cesne, Axel ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; DENOSUMAB; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; IFOSFAMIDE; IMATINIB; METHOTREXATE; TRABECTEDIN; VINCRISTINE;

ADJUVANT THERAPY; ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; DERMATOFIBROSARCOMA PROTUBERANS; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; EVIDENCE BASED MEDICINE; GASTROINTESTINAL STROMAL TUMOR; GIANT CELL TUMOR; HEALTH CARE QUALITY; HUMAN; LEIOMYOSARCOMA; MOLECULAR GENETICS; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; MYXOSARCOMA; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT COMPLIANCE; PROGRESSION FREE SURVIVAL; SOFT TISSUE SARCOMA; UTERUS SARCOMA;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; HUMANS; PROGNOSIS; SARCOMA;

EID: 79957989586     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-011-0145-5     Document Type: Article

References (43)

1. Delaney TF, Yang JC, Glatstein E. Adjuvant therapy for adult patients with soft tissue sarcomas. Oncology. 1991;5:105-18.
2. Brennan MF, Singer S, Maki R, et al. Sarcomas of the Soft Tissue and Bone. In: Devita VT, Lawrence TS, Rosenberg SA, editors. Cancer Principles and Practice of Oncology. 8th ed. Philadelphia: Lippincott Williams and Wilkins; 2008. p. 1741-94.
3. Bramwell V, Rouesse J, Steward W. Adjuvant CYVADIC Chemotherapy for Adult Soft Tissue Sarcoma-Reduced Local Recurrence but No Improvement in Survival: A Study of the European Organization for Research and Treatment of Cancer. Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1994;12:1137-49.
4. Sarcoma Meta-analysis Collaboration. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet. 1997;350:1647-54.
5. Jones GW, Chouinard M, Patel M. A systematic overview and quantitative meta-analysis. Clin Invest Med. 1991;14 suppl 19: A772.
6. Zalupski MM, Ryan JR, Hussein ME, et al. Defining the role of adjuvant chemotherapy for patients with soft tissue sarcoma of the extremities. In: Salmon SE, editor. Adjuvant therapy of cancer VII. Philadelphia: JB Lippincott; 1993. p. 385-92.
7. Tierney JF, Mosseri V, Stewart LA, et al. Adjuvant chemotherapy for soft-tissue sarcoma: review and metaanalysis of the published results of randomised clinical trials. Br J Cancer. 1995;72:469-75.
8. Brodowicz T, Schwameis E, Widder J, et al. Intensified adjuvant IFADIC chemotherapy for adult soft tissue sarcoma: a prospective randomized feasibility trial. Sarcoma. 2000;4:151-60. (Pubitemid 32055721)
9. Petrioli R, Coratti A, Correale P, et al. Adjuvant epirubicin with or without ifosfamide for adult softtissue sarcoma. Am J Clin Oncol. 2002;25(5):468-73. (Pubitemid 35154951)
10. Frustachi S, Gherlinzoni F, De Paoli A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian Randomised Cooperative Trial. J Clin Oncol. 2001;19:1238-47. (Pubitemid 32202526)
11. Cormier JN, Huang X, Xing Y, et al. Cohort analysis of patients with localized, high-risk, extremity softtissue sarcoma treated at two cancer centers: chemotherapy-associated outcomes. J Clin Oncol. 2004;22:4567-74. (Pubitemid 41185124)
12. Woll PJ, van Glabbeke M, Hohenberger A, et al.: Adjuvant chemotherapy (CT) with doxorubicin and ifosfamide in resected soft tissue sarcoma (STS): interim analysis of a randomized phase III trial. J Clin Oncol 2007, ASCO Annual Meeting Proceedings Part I. 25 (18S): 10008.
13. Le Cesne A, van Glabbeke M, Woll PJ, et al.: The end of adjuvant chemotherapy (adCT) era with doxorubicin-based regimen in resected high-grade soft-tissue sarcoma (STS): pooled analysis of the two STBSG-EORTC phase III clinical trials. J Clin Oncol 2008, 26: (May 20 suppl; abstr 10525).
14. Pervaiz N, Colterjohn N, Farrokhyar F, et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113:573-81.
15. Gortzak E, Azzarelli A, Buesa J, et al. A randomized phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. Eur J Cancer. 2001;37:1096-103.
16. O'Connor JM, Chacón, Petracci FE, et al.: Adjuvant chemotherapy in soft tissue sarcoma (STS): a metaanalysis of published data. J Clin Oncol 2008, 26: (May 20 suppl; abstr 10526).
17. Italiano A, Delva F, Mathoulin-Pelissier S, et al. Effect of adjuvant chemotherapy on survival in FNCLCC grade 3 soft tissue sarcomas: a multivariate analysis of the French Sarcoma Group Database. Ann Oncol. 2010;21(12):2436-41.
18. Sleijifer S, Ouali M, van Glabbeke M, et al. Prognostic and predictive factors for outcome to firstline ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Eur J Cancer. 2010;46(1):72-83.
19. Penel N, Bul BN, Bay JO, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIO-TAX study. J Clin Oncol. 2008;26(32):5269-74.
20. Le Cesne A, Blay JY, Judson I, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol. 2005;23(3):576-84. (Pubitemid 46224235)
21. Demetri GD, Chawla SP, von Mehren M, et al. Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules. J Clin Oncol. 2010;27(25):4188-96.
22. Judson IR, Blay J, Chawla SP, et al.: Trabectedin (Tr) in the treatment of advanced uterine leiomyosarcomas (U-LMS): Results of a pooled analysis of five single-agent phase II studies using the recommended dose. J Clin Oncol 2010, 28:15s (suppl; abstr 10028).
23. Hensley ML, Ishill N, Soslow R, et al. Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study. Gynecol Oncol. 2009;112:563-7.
24. Garcia Del Muro X, Fra J, Lopez Pousa A, et al.: Randomized phase II study of dacarbazine plus gemcitabine versus DTIC alone in patients with advanced soft tissue sarcoma: A Spanish Group for Research on Sarcomas (GEIS) study. J Clin Oncol 2009, 27:15s (suppl; abstr 10529).
25. Maki RG, Wathen JK, Patel SR, et al. Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002. J Clin Oncol. 2007;25(19):2755-63. (Pubitemid 47123184)
26. Pautier P, Bui Nguyen B, Penel S, et al.: Final results of a FNCLCC French Sarcoma Group multicenter randomized phase II study of gemcitabine (G) versus gemcitabine and docetaxel (G+D) in patients with metastatic or relapsed leiomyosarcoma (LMS). J Clin Oncol 2009, 27:15s (suppl; abstr 10527).
27. th Congress of the European Society of Medical Oncology. Milan; October 8-12, 2010. Abstract 13450.
28. Hensley ML, Wathen RG, Maki D, et al.: Adjuvant treatment of high-risk primary uterine leiomyosarcoma with gemcitabine/docetaxel (GT), followed by doxorubicin (D): Results of phase II multicenter trial SARC005. J Cin Oncol 2010, 28:15s) suppl; abstr 10021).
29. Chibon F, Lagarde P, Salas S, et al. Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nat Med. 2010;16(7):781-8.
30. Schöffski P. DNA repair functionality modulates the clinical outcome of patients with advanced sarcoma treated with trabectedin (ET-743). J Clin Oncol 2006, ASCO Annual Meeting Proceedings Part I Vol 24, No 18 S (June 20 Supplement), 2006:9522.
31. Ruiz-Soto R., Auger N., Tournay E. et al. Topoisomerase II-alpha protein expression and histological response following doxorubicin-based induction chemotherapy predict survival of locally advanced soft tissue sarcoma. EJC 2011, in press
32. De Matteo RP, Ballman KV, ANtonescu CR, et al.: Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373(9669):1097-104.
33. Schuetze S, Rutkowski P, Van Glabbeke MM, et al.: Combined analysis of two phase II trials of imatinib in advanced dermatofibrosarcoma protuberans (DFSP). J Clin Oncol 2009, 27:15s (suppl; abstr 10520).
34. Rutkowski P, Van Glabbeke M, Rankin CJ, et al. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: polled analysis of two phase II clinical trials. J Clin Oncol. 2010;28(10):1772-8.
35. Thomas D. M, S. Chawla, Skubitz K, et al. Denosumab for the treatment of giant cell tumor (GCT) of bone: Final results from a proof-of-concept, phase II study. J Clin Oncol. 2009, 27:15S (suppl; abstr 10510).
36. Grosso F, Jones RL, Demetri GD, et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 2007;8(7):595-602. (Pubitemid 46995623)
37. Gronchi A, Le Cesne A, Bui NB, et al.: A phase II clinical trial of neo-adjuvant trabectedin in patients with nonmetastatic advanced myxoid/round cell liposarcoma (MRCL). J Clin Oncol 2009, 27:15s (suppl; abstr 10520).
38. Gardner K, Judson I, Leahy M, et al.: Activity of cediranib, a highly potent and selective VEGF signaling inhibitor, in alveolar soft part sarcoma. J Clin Oncol 2009, 27 (15s) (suppl; abstr 10523).
39. Stacchiotti S, Tamborini E, Marrari A, et al. Response to sunitinib malate in advanced alveolar soft part sarcoma. Cancer Res. 2009;15(3):1096- 10104.
40. Maki RG, Keohan ML, Undevia SD, et al.: Updated results of a phase II study of oral multi-kinase inhibitor sorafenib in sarcomas, CTEP study 7060. J Clin Oncol 2008, 26 (15s) (suppl; abstr 10531).
41. Maki RG, D'Adamo DR, Keohan ML, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009;27(19):3133-40.
42. Vigil CE, Chiaporri AA, Williams CA et al. Phase II of sunitinib malate (SM) in patients with metastatic soft tissue sarcomas (STS) other than GIST: Results of a phase II study. J Clin Oncol 2008, 26 (suppl; abstract 10535).
43. Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib (GW786034) in patients (pts) with relapsed or refractory soft tissue sarcoma (STS); a phase II study from the EORTC STBSG (EORTC 62043). J Clin Oncol 2007, 25 (suppl; abstract 10031).